Myofascial Pelvic Pain
Myofascial pelvic pain (MFPP) is a chronic regional pain condition driven by hyperirritable trigger points within taut bands of the pelvic floor musculature — most commonly the levator ani (pubococcygeus, iliococcygeus, coccygeus) and obturator internus. It is reported in 22–94% of chronic pelvic pain populations depending on the case mix and rigor of the pelvic-floor exam, yet remains substantially underdiagnosed and underscreened because most providers do not perform a structured pelvic-floor myofascial examination.[1][2][3]
For the broader chronic pelvic pain framework (etiology by organ system, UPOINT phenotyping, pelvic congestion, pudendal neuralgia), see Chronic Pelvic Pain. For the bladder-specific phenotype, see IC/PBS.
Pathophysiology and Presentation
MFPP arises from dysfunction of the pelvic-floor muscles with development of myofascial trigger points (MTrPs) producing localized and referred pain. It may exist independently or co-occur with endometriosis, IC/BPS, vulvodynia, IBS, dyspareunia / vaginismus, and CP/CPPS in men, with viscero-somatic convergence amplifying both the pelvic-floor and visceral symptom burden.[1][2][4]
A recently described entity — myofascial urinary frequency syndrome — captures the subset of patients in whom pelvic-floor myofascial dysfunction drives lower-urinary-tract symptoms (frequency, urgency, sensation of incomplete emptying, suprapubic/bladder pressure) that are routinely misclassified as overactive bladder or IC/BPS.[5]
Typical clinical features:
- Pelvic, perineal, vulvar, or suprapubic pain
- Dyspareunia, post-coital pain, sexual dysfunction
- Urinary frequency, urgency, hesitancy, or incomplete emptying
- Pain with prolonged sitting
- Referred pain to low back, thighs, abdomen, and rectum
Diagnosis
Diagnosis is clinical and exam-based. There is no validated imaging, biomarker, or laboratory test.[6]
Pelvic-floor myofascial examination
- Single-digit transvaginal (or transrectal) palpation of the levator-ani complex and obturator internus, sweeping each muscle group and laterality.[6]
- Assess for taut bands, trigger points, hypertonicity, and reproduction of the patient's typical pain with focal pressure.
- The ACOG Practice Bulletin 218 explicitly directs particular attention to the abdominal and pelvic neuromusculoskeletal exam.[7]
Persistency Index
The Persistency Index (Ackerman 2023) is a patient-reported screening tool that identifies myofascial urinary frequency syndrome from symptom severity alone — incorporating the persistent nature of incomplete-emptying sensation, dyspareunia, and age. A score ≥ 7 discriminates myofascial dysfunction from non-myofascial LUTS (AUC 0.74), allowing primary clinicians to triage patients to a structured pelvic-floor exam.[5]
Stepwise Management
The multimodal pathway recommended by ACOG Practice Bulletin 218 (Level B), the AUA IC/BPS Guideline (2022), and contemporary consensus reviews escalates as follows.[7][8][2]
| Step | Intervention | Trigger to escalate |
|---|---|---|
| 1 | Pelvic floor physical therapy (PFPT) ± oral pharmacotherapy | First-line for all patients |
| 2 | Trigger point injections (TPIs) with local anesthetic | Refractory to PFPT, flare, or unable to tolerate manual therapy |
| 3 | OnabotulinumtoxinA injection | Repeated TPIs without durable relief, or barriers to monthly visits |
| 4 | Compounded intravaginal adjuncts + neuromodulators | Throughout; not stand-alone |
Kegel exercises are contraindicated in hypertonic pelvic-floor dysfunction — strengthening worsens the underlying state. PFPT for MFPP is down-training, not strengthening.[9][7] Opioids are not recommended.[7][2]
I. Pelvic Floor Physical Therapy
PFPT is the cornerstone — high-certainty evidence for short-term pain reduction in CPP populations and the only first-line intervention.[7][2][9]
| Modality | Technique | Goal |
|---|---|---|
| Internal myofascial release | Single-digit transvaginal/transrectal palpation of levator ani and obturator internus with sustained pressure to taut bands and MTrPs; 30–60 min sessions, 1–2× per week for 8–12 weeks | Release fascial restrictions, reduce trigger-point irritability |
| Biofeedback (down-training) | Surface or intracavitary EMG with real-time feedback | Train pelvic-floor relaxation, not strength |
| Electrical stimulation | Low-frequency TENS or interferential current, external or intravaginal | Pain modulation, muscle relaxation |
| Pelvic-floor stretching / home program | Reverse Kegels, child's pose, deep squat, diaphragmatic breathing | Sustain in-clinic gains |
A 2025 trial of postpartum pelvic-floor hypertonia found that lifestyle intervention + biofeedback/electrical stimulation + manual myofascial release achieved a 94.3% effective rate, significantly superior to electrical stimulation/biofeedback alone (87%) or lifestyle alone (37.7%) — supporting combined rather than single-modality protocols.[10]
II. Trigger Point Injections (TPIs)
ACOG Practice Bulletin 218 recommends TPIs (Level B) to improve pain and functional ability in myofascial CPP — alone or with other modalities.[7] Effects appear largely independent of injectant, raising the possibility that needle insertion itself delivers a therapeutic mechanical or strong placebo response.[7][11]
Injectant options
| Injectant | Notes | Evidence |
|---|---|---|
| Local anesthetic (lidocaine, bupivacaine, levobupivacaine, mepivacaine) | Most commonly used; well-studied | Multiple cohorts and RCTs[12][13][14] |
| Local anesthetic + corticosteroid (triamcinolone, betamethasone) | Common in postpartum and refractory MFPP | A 2025 RCT found levobupivacaine alone non-inferior to levobupivacaine + betamethasone for postpartum myofascial perineal pain[13]; 2025 ASRA/AAPM guideline notes no controlled head-to-head data for vaginal TPIs[15] |
| Magnesium-based formulation | Novel approach | RCT showed clinically meaningful pain reduction (~2.6 points / 10) comparable to lidocaine[11] |
| Normal saline | Mechanical / needling effect | Comparable to active injectants in several trials[7] |
| OnabotulinumtoxinA | For refractory / repeated-TPI patients | See Section III |
Office-based transvaginal TPI — published protocols
| Protocol | Injectant | Volume per TrP | Delivery |
|---|---|---|---|
| Langford 2007 | 0.25% bupivacaine 10 mL + 2% lidocaine 10 mL + triamcinolone 40 mg / 1 mL | 5 mL per trigger point | 5.5" Iowa-trumpet pudendal needle guide; office, no sedation[12] |
| Leitch 2022 (RCT) | 1% lidocaine 10 mL or magnesium-based formulation | Per trigger point | Transvaginal, office; 8 sessions over 12 weeks[11] |
| Solano Calvo 2025 (RCT) | Levobupivacaine 5 mg/mL ± betamethasone 3 mg/mL | Per trigger point | Transvaginal, office[13] |
| Moya Esteban 2019 | Mepivacaine 2% (8 mL) + betamethasone acetate (2 mL) | Per trigger point | Transvaginal, office[14] |
Step-by-step technique
- Position: dorsal lithotomy; sedation usually not required.
- Exam: single-digit transvaginal palpation of pubococcygeus, iliococcygeus, coccygeus, and obturator internus bilaterally; identify trigger points by reproduction of the patient's pain.[12][6]
- Needle guidance: Iowa-trumpet pudendal needle guide (5.5") or pudendal-block kit (≈ 1 cm depth of penetration); the guide is held transvaginally with the index finger directing the needle tip onto the trigger point.[12]
- Injection: advance into the trigger point under digital guidance; aspirate to confirm no vascular entry; inject 1–5 mL of injectant per point. Multiple trigger points may be addressed in a single session.
- Post-procedure: brief observation; teach pelvic-floor stretching for home use; resume PFPT.[12]
Frequency and pairing with PFPT
- Every 2–4 weeks; the Leitch RCT used 8 sessions over 12 weeks for clinically meaningful pain reduction.[11]
- TPI immediately followed by myofascial-release PFPT in the same visit produced a median VAS reduction of 4 points vs 2 points with TPI alone (p = 0.042); 77% vs 45% achieved ≥ 3-point improvement (p = 0.008).[16]
III. OnabotulinumtoxinA (Botox)
OnabotulinumtoxinA (BTA) is reserved for patients requiring repeated long-term TPIs, those with barriers to monthly visits, and those without durable improvement from anesthetic TPIs after PFPT.[17][18] This is an off-label use — pelvic-floor MFPP is not on the FDA label.[17]
Dosing
| Dose | Dilution | Approach | Anesthesia | Note |
|---|---|---|---|---|
| 200 U (most studied) | 200 U in 20 mL normal saline (10 U/mL) | Transvaginal | Conscious sedation or general | Whitmore 2025 protocol[17]; Dessie RCT[19] |
| 80 U | Variable | Transvaginal | General | Abbott 2006 RCT[20] |
| 50–200 U range | Variable | Transvaginal | Variable | Observational; no dose-response difference for efficacy, but higher AE rates with higher doses[21][22] |
Step-by-step technique (Whitmore 2025)
- Awake exam — palpate pubococcygeus, iliococcygeus, and obturator internus bilaterally; mark hypertonic / tender targets.[17]
- Sedation — conscious sedation or general anesthesia; some centers use local-only office protocols.
- Reconstitution — 200 U onabotulinumtoxinA in 20 mL normal saline (10 U/mL).
- Needle — pudendal-block kit, ~1 cm depth of penetration.
- Injection — sequentially deliver 1–2 mL (10–20 U) at multiple sites along each affected muscle, distributed across pubococcygeus, iliococcygeus, and obturator internus bilaterally.
- Image-guided alternative — 4D transperineal ultrasound can confirm intramuscular needle placement and visualize fluid tracking along muscle fibers.[23]
- Standardized ten-point method — a 2026 trial described a fixed ten-site anatomical injection pattern (rather than trigger-point-dependent placement) with comparable efficacy to trigger-point-guided injection plus shorter learning curve, less procedure time, and less patient discomfort.[24]
Concurrent pudendal nerve block — limited benefit
- A 12-year, 182-patient retrospective cohort found no difference in clinical outcomes, re-intervention, or AEs between BTA alone vs BTA + pudendal block.[18]
- A 96-event subgroup analysis found no difference in PACU pain (VAS 1.7 vs 1.9), PACU time, or opioid requirements.[25]
Onset, duration, retreatment
- Onset of pain reduction: ~6 weeks post-injection.[17]
- Peak effect: 6–12 weeks.[17][26]
- Duration: ~3–6 months; median time to re-intervention 6 months.[17][18]
- Mean number of total injections per patient: 1.6–1.7 in a large cohort — many require retreatment.[18]
Efficacy — mixed
| Study | Design / N | Result |
|---|---|---|
| Dessie 2019 RCT | n = 59; 200 U BTA vs saline (all received PFPT from week 4) | Not superior to saline for pain on palpation at 2/4/12 weeks; BTA more likely to report PGI-I global improvement at 4 weeks (p = 0.03)[19] |
| Abbott 2006 RCT | n = 60; 80 U BTA | Significantly reduced pelvic-floor resting pressure (49 → 32 cmH₂O) and dyspareunia VAS[20] |
| Jha 2021 observational | n = 48 | 74% improvement; no efficacy difference across 50–200 U dose range[21] |
| Mooney 2021 pilot | n = 21 | Improvement in dyspareunia, sexual function, QoL; 4 previously apareunic patients regained penetrative intercourse[26] |
| Lewis 2023 12-year cohort | n = 182 | Median time to re-intervention 6 months; safety profile across long-term repeat dosing[18] |
Adverse events
| AE | Incidence | Notes |
|---|---|---|
| Constipation | 6.6–10.1% | Most common; usually transient[17][18] |
| Urinary incontinence | up to 22% | More common at higher doses[17][22] |
| Urinary retention | 3.8% | [18] |
| Urinary tract infection | 2.7–9% | [18] |
| Fecal incontinence | 2.7% | Transient (~2 weeks); more frequent at higher doses[18][22] |
| Worsening pelvic pain | 11.5% | [18] |
IV. Compounded Intravaginal Pharmacotherapy
These are off-label, non-FDA-approved, and rely on compounding-pharmacy formulations whose bioavailability and stability vary between pharmacies. They are adjuncts within a multimodal plan — not stand-alone therapies — and the evidence base is dominated by small studies, case reports, and expert opinion.[2][27][9]
Intravaginal diazepam — most studied
- Dose: 5–10 mg suppository, nightly or intermittent.
- Pharmacokinetics: vaginal administration produces a lower peak (Cmax ~31 ng/mL at ~3.1 h) and lower bioavailability (70.5%) than oral, but a prolonged half-life (~82 h) with active nordiazepam metabolite peaking at ~132 h. Steady-state takes ~1 week — accumulation favors intermittent dosing (e.g., before PT or intercourse) rather than daily use.[28]
- Evidence is mixed:
- Observational series report subjective improvement in 71–96% with improved pelvic-floor tone on perineometry.[29]
- A triple-blinded RCT (10 mg nightly × 28 days) found no improvement in resting EMG, FSFI, or VAS vs placebo as monotherapy.[30]
- Combined with TENS, vaginal diazepam significantly improved dyspareunia and pelvic-floor relaxation after contraction vs TENS alone.[31]
- A systematic review concluded that intravaginal diazepam may be helpful in high-tone pelvic-floor dysfunction but is insufficient as monotherapy — best as an adjunct to PFPT or TPIs.[32]
- Side effects: fatigue is most common; sedation; benzodiazepine-class precautions.[28]
Intravaginal / topical baclofen
- GABA-B receptor agonist with antispastic and analgesic effects.[33]
- Formulation: 5% topical cream, or compounded vaginal suppository (5–10 mg), often paired with palmitoylethanolamide (PEA) or amitriptyline.
- Evidence: limited to case reports and small series in vulvodynia and proctodynia (>50% symptom reduction with 5% cream + PEA; resumption of sexual activity).[34][35] Amitriptyline-baclofen creams have shown pre-to-post improvement in non-RCT vulvodynia studies.[36] No RCTs of intravaginal baclofen alone for pelvic-floor MFPP.
- Mechanism: acts at peripheral GABA-B receptors on nociceptor terminals and modulates nociceptor / immunocompetent / epithelial cross-talk in vulvar / vaginal mucosa; centrally reduces spasticity.[33][35]
- Safety: systemic absorption is presumed lower than oral; oral baclofen carries sedation, dizziness, and a withdrawal syndrome requiring taper. Formal vaginal-baclofen PK data are lacking.[33]
Intravaginal / topical ketamine
- NMDA-receptor antagonist; rationale is modulation of peripheral sensitization at nociceptor afferents.[37]
- Formulation: 2–10% cream or suppository, often in combination with amitriptyline, lidocaine, or baclofen.
- Evidence is weak:
- A 2025 Cochrane review found very uncertain evidence that topical ketamine improves pain vs placebo (MD 1.90, 95% CI −18.73 to 22.53, immediate-term).[38]
- Small studies of topical ketamine alone show no statistically significant benefit for neuropathic pain.
- Combination topical formulations (ketamine + amitriptyline, ketamine + lidocaine) show 40–75% response in retrospective non-placebo-controlled analyses; optimal dosing and combinations remain unclear.
- No RCTs of intravaginal ketamine for MFPP or vulvodynia.
- Safety: psychomimetic effects, unclear long-term cognitive impact, addiction risk. Chronic systemic ketamine causes ketamine cystitis (bladder inflammation / fibrosis) — particularly relevant in the urologic context, though not reported with low-dose topical / vaginal use.[37]
Summary of compounded intravaginal agents
| Agent | Typical vaginal dose | Mechanism | Evidence | Bottom line |
|---|---|---|---|---|
| Diazepam | 5–10 mg suppository | GABA-A agonist | RCT + observational, mixed | Insufficient as monotherapy; useful adjunct to TENS / PFPT; intermittent dosing preferred[28][30][31][32] |
| Baclofen | 5% cream or 5–10 mg suppository | GABA-B agonist | Case reports / series | No RCT for vaginal use; topical 5% + PEA promising in vulvodynia[34][35] |
| Ketamine | 2–10% cream / suppository | NMDA antagonist | Very low certainty | No benefit over placebo for topical alone; combination products only[38] |
V. Practical Treatment Ladder
- Weeks 1–12 — PFPT (1–2× per week) with internal myofascial release, biofeedback down-training, electrical stimulation, and a home stretching program. Concurrent pharmacotherapy (cyclobenzaprine, gabapentin, SNRI, TCA) as warranted by phenotype.[7][2][9]
- Inadequate response or flare — office-based transvaginal TPIs with local anesthetic (e.g., bupivacaine / lidocaine, with or without steroid) every 2–4 weeks; schedule PFPT immediately after each TPI for additive effect.[12][16]
- Repeated TPIs without durable relief — escalate to onabotulinumtoxinA 100–200 U transvaginal injection under sedation; resume PFPT 4–6 weeks post-injection when effect begins.[17][19]
- Adjuncts throughout — intermittent intravaginal diazepam (5–10 mg, before PT or intercourse), topical baclofen, or combination compounded agents.[28][35]
- Re-assess at 8–12 weeks after each step. Refractory patients warrant pain-medicine referral for pudendal nerve blocks, neuromodulation, or multidisciplinary chronic-pain management.[7]
- Combined neuromuscular protocol — ultrasound-guided peripheral nerve blocks + TPIs + weekly PFPT × 6 weeks produced significant VAS improvement (6.61 → 4.47) in 186 women with CPP.[39]
Key Principles
- MFPP contributes to 22–94% of CPP cases and is the most commonly overlooked pain generator — driven by absence of a structured pelvic-floor exam.[1][2]
- Diagnosis is exam-based: single-digit transvaginal/transrectal palpation reproducing the patient's pain.[6]
- Kegel exercises are contraindicated; PFPT for MFPP is down-training, not strengthening.[9]
- TPIs work largely independent of injectant — local anesthetic, magnesium, and saline have all shown comparable benefit, suggesting needling is part of the mechanism.[7][11]
- Pair TPIs with immediate post-injection PFPT for greater pain reduction than TPI alone.[16]
- OnabotulinumtoxinA is reserved for refractory patients; ~6 weeks to onset, 3–6 months duration; higher doses do not improve efficacy but increase AEs (UI, fecal incontinence).[18][22]
- Concurrent pudendal block at the time of BTA does not improve outcomes — neither in clinical follow-up nor in PACU pain.[18][25]
- Compounded intravaginal agents are adjuncts only; intravaginal diazepam fails as monotherapy but helps when paired with TENS or PFPT; baclofen and ketamine evidence is weak.[30][32][38]
- Opioids are not recommended for MFPP.[7][2]
References
1. Ross V, Detterman C, Hallisey A. Myofascial pelvic pain: an overlooked and treatable cause of chronic pelvic pain. J Midwifery Womens Health. 2021;66(2):148-160. doi:10.1111/jmwh.13224.
2. Namazi G, Chauhan N, Handler S. Myofascial pelvic pain: the forgotten player in chronic pelvic pain. Curr Opin Obstet Gynecol. 2024;36(4):273-281. doi:10.1097/GCO.0000000000000966.
3. Steen JP, Jaiswal KS, Kumbhare D. Myofascial pain syndrome: an update on clinical characteristics, etiopathogenesis, diagnosis, and treatment. Muscle Nerve. 2025;71(5):889-910. doi:10.1002/mus.28377.
4. Lamvu G, Carrillo J, Ouyang C, Rapkin A. Chronic pelvic pain in women: a review. JAMA. 2021;325(23):2381-2391. doi:10.1001/jama.2021.2631.
5. Ackerman AL, Torosis M, Jackson NJ, et al. The Persistency Index: a novel screening tool for identifying myofascial pelvic floor dysfunction in patients seeking care for lower urinary tract symptoms. Am J Obstet Gynecol. 2023;229(6):667.e1-667.e11. doi:10.1016/j.ajog.2023.08.017.
6. Meister MR, Shivakumar N, Sutcliffe S, Spitznagle T, Lowder JL. Physical examination techniques for the assessment of pelvic floor myofascial pain: a systematic review. Am J Obstet Gynecol. 2018;219(5):497.e1-497.e13. doi:10.1016/j.ajog.2018.06.014.
7. Committee on Practice Bulletins—Gynecology. Chronic pelvic pain: ACOG Practice Bulletin, Number 218. Obstet Gynecol. 2020;135(3):e98-e109. doi:10.1097/AOG.0000000000003716.
8. Clemens JQ, Erickson DR, Varela NP, Lai HH. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2022;208(1):34-42. doi:10.1097/JU.0000000000002756.
9. Wallace SL, Miller LD, Mishra K. Pelvic floor physical therapy in the treatment of pelvic floor dysfunction in women. Curr Opin Obstet Gynecol. 2019;31(6):485-493. doi:10.1097/GCO.0000000000000584.
10. Xu Y, Li C, Li J. Comparison of the efficacy of three intervention schemes for postpartum pelvic floor muscle hypertonia. Int Urogynecol J. 2025. doi:10.1007/s00192-025-06128-8.
11. Leitch J, Webb A, Pudwell J, et al. Magnesium-based trigger point infiltrations versus local anaesthetic infiltrations in chronic pelvic myofascial pain: a randomized, double-blind, controlled study. J Obstet Gynaecol Can. 2022;44(8):877-885. doi:10.1016/j.jogc.2022.02.129.
12. Langford CF, Udvari Nagy S, Ghoniem GM. Levator ani trigger point injections: an underutilized treatment for chronic pelvic pain. Neurourol Urodyn. 2007;26(1):59-62. doi:10.1002/nau.20393.
13. Solano Calvo JA, Barreiro García JM, González Hinojosa J, et al. Treatment of postpartum myofascial perineal pain and dyspareunia through local anaesthetic infiltrations compared to anaesthetic and corticosteroids: a randomised double-blind clinical trial. J Clin Med. 2025;14(9):3228. doi:10.3390/jcm14093228.
14. Moya Esteban BM, Solano Calvo JA, Torres Morcillo C, et al. Retrospective case review of combined local mepivacaine and steroid injections into vaginal trigger points for the management of moderate-to-severe perineal pain after childbirth. Arch Gynecol Obstet. 2019;299(2):501-505. doi:10.1007/s00404-018-5000-5.
15. Benzon HT, Elmofty D, Shankar H, et al. Use of corticosteroids for adult chronic pain interventions: sympathetic and peripheral nerve blocks, trigger point injections — guidelines from the ASRA, AAPM, ASIPP, and IPSIS. Reg Anesth Pain Med. 2025. doi:10.1136/rapm-2024-105593.
16. Lewis GK, Chen AH, Craver EC, Crook JE, Carrubba AR. Trigger point injections followed by immediate myofascial release in the treatment of pelvic floor tension myalgia. Arch Gynecol Obstet. 2023;307(4):1027-1035. doi:10.1007/s00404-022-06880-y.
17. Whitmore GT, Tam J, Orlando M. Onabotulinumtoxin A injections for patients with pelvic floor dysfunction. J Minim Invasive Gynecol. 2025. doi:10.1016/j.jmig.2025.07.005.
18. Lewis GK, Carrubba AR, Stanton AP, et al. OnabotulinumtoxinA injections for the treatment of myofascial pelvic pain: 12-year experience at a tertiary care academic center. Gynecol Obstet Invest. 2023;88(1):37-46. doi:10.1159/000528177.
19. Dessie SG, Von Bargen E, Hacker MR, Haviland MJ, Elkadry E. A randomized, double-blind, placebo-controlled trial of onabotulinumtoxin A trigger point injections for myofascial pelvic pain. Am J Obstet Gynecol. 2019;221(5):517.e1-517.e9. doi:10.1016/j.ajog.2019.06.044.
20. Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006;108(4):915-23. doi:10.1097/01.AOG.0000237100.29870.cc.
21. Jha S, Toozs-Hobson P, Roper JC, et al. Botulinum injections for myofascial pelvic pain. Int Urogynecol J. 2021;32(5):1151-1156. doi:10.1007/s00192-020-04435-w.
22. Karp BI, Tandon H, Vigil D, Stratton P. Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders. Int Urogynecol J. 2019;30(7):1071-1081. doi:10.1007/s00192-018-3831-z.
23. Nesbitt-Hawes EM, Dietz HP, Abbott JA. Four-dimensional ultrasound guidance for pelvic floor botulinum toxin-A injection in chronic pelvic pain: a novel technique. Ultrasound Obstet Gynecol. 2018;51(3):396-400. doi:10.1002/uog.17537.
24. Yang J, Ma X, Luo C, et al. The significance of type A botulinum toxin ten-point injection therapy in the treatment of chronic pelvic pain caused by muscle spasms in women. Int Urogynecol J. 2026;37(4):963-972. doi:10.1007/s00192-025-06346-0.
25. Coombs P, Lewis G, Chen AH, Ma Y, Carrubba AR. Does pudendal nerve block improve perioperative pain following onabotulinumtoxinA injection for myofascial pelvic pain? Eur J Obstet Gynecol Reprod Biol. 2025;306:64-68. doi:10.1016/j.ejogrb.2024.12.055.
26. Mooney SS, Readman E, Hiscock RJ, et al. Botulinum toxin A (Botox) injection into muscles of pelvic floor as a treatment for persistent pelvic pain secondary to pelvic floor muscular spasm: a pilot study. Aust N Z J Obstet Gynaecol. 2021;61(5):777-784. doi:10.1111/ajo.13396.
27. Flatow V, Uy-Kroh J, Carey ET, Ascher-Walsh C, Khalil S. Skeletal muscle relaxants for the treatment of myofascial pelvic pain and high tone pelvic floor disorders. Curr Opin Obstet Gynecol. 2023;35(4):311-315. doi:10.1097/GCO.0000000000000894.
28. Larish AM, Dickson RR, Kudgus RA, et al. Vaginal diazepam for nonrelaxing pelvic floor dysfunction: the pharmacokinetic profile. J Sex Med. 2019;16(6):763-766. doi:10.1016/j.jsxm.2019.03.003.
29. Rogalski MJ, Kellogg-Spadt S, Hoffmann AR, Fariello JY, Whitmore KE. Retrospective chart review of vaginal diazepam suppository use in high-tone pelvic floor dysfunction. Int Urogynecol J. 2010;21(7):895-9. doi:10.1007/s00192-009-1075-7.
30. Crisp CC, Vaccaro CM, Estanol MV, et al. Intra-vaginal diazepam for high-tone pelvic floor dysfunction: a randomized placebo-controlled trial. Int Urogynecol J. 2013;24(11):1915-23. doi:10.1007/s00192-013-2108-9.
31. Murina F, Felice R, Di Francesco S, Oneda S. Vaginal diazepam plus transcutaneous electrical nerve stimulation to treat vestibulodynia: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2018;228:148-153. doi:10.1016/j.ejogrb.2018.06.026.
32. Stone RH, Abousaud M, Abousaud A, Kobak W. A systematic review of intravaginal diazepam for the treatment of pelvic floor hypertonic disorder. J Clin Pharmacol. 2020;60 Suppl 2:S110-S120. doi:10.1002/jcph.1775.
33. Fromm GH. Baclofen as an adjuvant analgesic. J Pain Symptom Manage. 1994;9(8):500-9. doi:10.1016/0885-3924(94)90111-2.
34. Keppel Hesselink JM, Kopsky DJ, Sajben NL. Vulvodynia and proctodynia treated with topical baclofen 5% and palmitoylethanolamide. Arch Gynecol Obstet. 2014;290(2):389-93. doi:10.1007/s00404-014-3218-4.
35. Keppel Hesselink JM, Kopsky DJ, Sajben N. New topical treatment of vulvodynia based on the pathogenetic role of cross talk between nociceptors, immunocompetent cells, and epithelial cells. J Pain Res. 2016;9:757-762. doi:10.2147/JPR.S115407.
36. Schlaeger JM, Glayzer JE, Villegas-Downs M, et al. Evaluation and treatment of vulvodynia: state of the science. J Midwifery Womens Health. 2023;68(1):9-34. doi:10.1111/jmwh.13456.
37. Pickering G, Morel V, Voute M. Managing chronic pain: the ketamine option. CNS Drugs. 2025. doi:10.1007/s40263-025-01234-z.
38. Ferraro MC, Cashin AG, Visser EJ, et al. Ketamine and other NMDA receptor antagonists for chronic pain. Cochrane Database Syst Rev. 2025;8:CD015373. doi:10.1002/14651858.CD015373.pub2.
39. Patil S, Daniel G, Vyas R, et al. Neuromuscular treatment approach for women with chronic pelvic pain syndrome improving pelvic pain and functionality. Neurourol Urodyn. 2022;41(1):220-228. doi:10.1002/nau.24799.